• Seaport Therapeutics reported positive topline Phase 1 driving simulator results for GlyphAllo, its oral prodrug of allopregnanolone.
• Evening dosing at 375 mg showed no next-morning driving impairment versus placebo following multiple-day dosing; a single 250 mg dose also showed no impairment.
• Zopiclone, used as a positive control, caused next-morning impairment, supporting the study’s ability to detect driving effects.
• No serious adverse events were reported; most side effects were mild and transient.
• Results will be submitted to the FDA; additional analyses are planned for future scientific meetings; BUOY-1 Phase 2b MDD topline data is expected in H1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seaport Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609090700BIZWIRE_USPR_____20260909_BW055068) on September 09, 2026, and is solely responsible for the information contained therein.